DrugPatentWatch Database Preview
Methotrexate sodium - Generic Drug Details
What are the generic drug sources for methotrexate sodium and what is the scope of methotrexate sodium freedom to operate?
Methotrexate sodium has two patent family members in two countries.
There are twenty drug master file entries for methotrexate sodium. Twenty-six suppliers are listed for this compound.
Summary for methotrexate sodium
| International Patents: | 2 |
| US Patents: | 2 |
| Tradenames: | 12 |
| Applicants: | 23 |
| NDAs: | 46 |
| Drug Master File Entries: | 20 |
| Suppliers / Packagers: | 26 |
| Bulk Api Vendors: | 98 |
| Clinical Trials: | 3,962 |
| Patent Applications: | 7,393 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | see low prices |
| DailyMed Link: | methotrexate sodium at DailyMed |
Pharmacology for methotrexate sodium
| Drug Class | Folate Analog Metabolic Inhibitor |
| Mechanism of Action | Folic Acid Metabolism Inhibitors |
Synonyms for methotrexate sodium
| (+)-4-Amino-10-methylfolic acid |
| (2S)-2-[(4-([(2,4-DIAMINOPTERIDIN-6-YL)METHYL](METHYL)AMINO)PHENYL)FORMAMIDO]PENTANEDIOIC ACID |
| (2S)-2-[(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}phenyl)formamido]pentanedioic acid |
| (2S)-2-[[[4-[(2,4-diamino-6-pteridinyl)methyl-methylamino]phenyl]-oxomethyl]amino]pentanedioic acid;hydrate |
| (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methyl-amino]benzoyl]amino]glutaric acid;hydrate |
| (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methyl-amino]benzoyl]amino]pentanedioic acid |
| (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid |
| (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid;hydrate |
| (2S)-2-[[4-[[2,4-bis(azanyl)pteridin-6-yl]methyl-methyl-amino]phenyl]carbonylamino]pentanedioic acid;hydrate |
| (4-(((2,4-diaminopteridin-6-yl)methyl)(methyl)amino)benzoyl)-L-glutamic acid |
| (S)-2-(4-(((2,4-Diaminopteridin-6-yl)methyl)(methyl)amino)benzamido)pentanedioic acid |
| (S)-2-(4-[(2,4-DIAMINO-PTERIDIN-6-YLMETHYL)-METHYL-AMINO]-BENZOYLAMINO)-PENTANEDIOIC ACID |
| [3H]-methotrexate |
| [3H]methotrexate |
| 1082707-84-3 |
| 133073-73-1 |
| 15475-56-6 |
| 15475-56-6 (hydrochloride salt) |
| 1771-EP0930075A1 |
| 1771-EP2269989A1 |
| 1771-EP2269994A1 |
| 1771-EP2270001A1 |
| 1771-EP2270008A1 |
| 1771-EP2270018A1 |
| 1771-EP2270505A1 |
| 1771-EP2272825A2 |
| 1771-EP2272827A1 |
| 1771-EP2272832A1 |
| 1771-EP2275413A1 |
| 1771-EP2275420A1 |
| 1771-EP2277565A2 |
| 1771-EP2277566A2 |
| 1771-EP2277567A1 |
| 1771-EP2277568A2 |
| 1771-EP2277569A2 |
| 1771-EP2277570A2 |
| 1771-EP2277865A1 |
| 1771-EP2277876A1 |
| 1771-EP2280012A2 |
| 1771-EP2281563A1 |
| 1771-EP2281815A1 |
| 1771-EP2287156A1 |
| 1771-EP2289892A1 |
| 1771-EP2289894A2 |
| 1771-EP2292233A2 |
| 1771-EP2292280A1 |
| 1771-EP2292595A1 |
| 1771-EP2292614A1 |
| 1771-EP2292615A1 |
| 1771-EP2292617A1 |
| 1771-EP2295055A2 |
| 1771-EP2295416A2 |
| 1771-EP2295426A1 |
| 1771-EP2295427A1 |
| 1771-EP2298743A1 |
| 1771-EP2298748A2 |
| 1771-EP2298764A1 |
| 1771-EP2298765A1 |
| 1771-EP2298768A1 |
| 1771-EP2298772A1 |
| 1771-EP2298778A1 |
| 1771-EP2298780A1 |
| 1771-EP2301928A1 |
| 1771-EP2301933A1 |
| 1771-EP2305243A1 |
| 1771-EP2305640A2 |
| 1771-EP2305642A2 |
| 1771-EP2305660A1 |
| 1771-EP2305668A1 |
| 1771-EP2305671A1 |
| 1771-EP2305679A1 |
| 1771-EP2305689A1 |
| 1771-EP2308833A2 |
| 1771-EP2308839A1 |
| 1771-EP2308855A1 |
| 1771-EP2308861A1 |
| 1771-EP2311453A1 |
| 1771-EP2311807A1 |
| 1771-EP2311808A1 |
| 1771-EP2311825A1 |
| 1771-EP2311827A1 |
| 1771-EP2311829A1 |
| 1771-EP2311840A1 |
| 1771-EP2311842A2 |
| 1771-EP2311850A1 |
| 1771-EP2314590A1 |
| 1771-EP2316459A1 |
| 1771-EP2316832A1 |
| 1771-EP2316833A1 |
| 1771-EP2316834A1 |
| 1771-EP2371811A2 |
| 1771-EP2374454A1 |
| 1dhi |
| 1dhj |
| 2,2'-(9,10-anthracenediylidene)-bis-propanedinitrile |
| 2drc |
| 4-Amino-10-methylfolic acid |
| 4-Amino-10-methylfolic acid hydrate |
| 4-amino-N(10)-methylpteroylglutamic acid |
| 4-Amino-N(sup 10)-methylpteroylglutamic acid |
| 4-Amino-N10-methylpteroyl glutamate sodium |
| 4-Amino-N10-methylpteroyl-L-glutamic acid |
| 4-Aminomethylpteroylglutamic acid |
| 4kn0 |
| 4ocx |
| 59-05-2 |
| 59-05-2 (Parent) |
| 5947-EP0930075A1 |
| 5947-EP2269994A1 |
| 5947-EP2289892A1 |
| 70359-39-6 |
| 73M731 |
| 7413-34-5 (di-hydrochloride salt) |
| 7532-09-4 |
| A-2190 |
| A-Methopterin |
| A-Methpterin |
| AB02593 |
| Abitextrate |
| Abitrexate |
| Abitrexate (Methotrexate) |
| AC1L2R79 |
| ACT03341 |
| AI3-25299 |
| AJ-26587 |
| AK-77824 |
| AK340946 |
| AKOS016340329 |
| Amethopterin |
| Amethopterin L- |
| Amethopterine |
| An-PDN |
| Antifolan |
| Antifolan hydrate |
| ANW-72813 |
| AOB5585 |
| APC-2002 |
| Arbitrexate |
| BC202627 |
| BDBM18050 |
| BDBM66082 |
| BIDD:PXR0175 |
| Bio-0134 |
| Bio1_000486 |
| Bio1_000975 |
| Bio1_001464 |
| BR-77824 |
| BRD-K59456551-001-09-3 |
| Brimexate |
| C01937 |
| C20H22N8O5 |
| CAS-59-05-2 |
| CCG-35800 |
| CCRIS 1109 |
| CHEBI:44185 |
| CHEMBL34259 |
| cid_126941 |
| cid_165528 |
| CL 14377 |
| CL-14377 |
| CS-1732 |
| CTK1G9789 |
| D00142 |
| D02115 |
| D07ALU |
| D0D3DU |
| D0SV8E |
| DB00563 |
| DivK1c_000114 |
| DL-4-Amino-N10-methylpteroylglutamic acid hydrate |
| DL-Amethopterin hydrate |
| DR002811 |
| DSSTox_CID_822 |
| DSSTox_GSID_20822 |
| DSSTox_RID_75810 |
| DTXSID4020822 |
| EINECS 200-413-8 |
| EINECS 231-398-6 |
| EINECS 239-495-5 |
| EMT 25,299 |
| Emtexate |
| Emthexat |
| Emthexate |
| EU-0100020 |
| Fauldexato |
| FBOZXECLQNJBKD-ZDUSSCGKSA-N |
| Folex |
| Folex Pfs |
| Folex-Pfs |
| folic acid antagonist |
| FT-0082628 |
| FT-0601523 |
| g301 |
| Glutamic acid, N-(p-(((2,4-diamino-6-pteridinyl)methyl)methylamino)benzoyl)-, L- |
| Glutamic acid, N-(p-(((2,4-diamino-6-pteridinyl)methyl)methylamino)benzoyl)-, sodium salt |
| Glutamic acid,4-diamino-6-pteridinyl)methyl] methylamino]benzoyl]-, L-(+)- |
| GTPL4674 |
| GTPL4815 |
| Hdmtx |
| HE357164 |
| HMS1568K12 |
| HMS2095K12 |
| HMS2233O18 |
| HMS3260C21 |
| HMS500F16 |
| HSDB 3123 |
| HY-14519 |
| I06-2098 |
| I14-18123 |
| IDI1_000114 |
| Intradose-MTX |
| Intrathecal methotrexate |
| J10045 |
| KBio1_000114 |
| KBio2_002338 |
| KBio2_004906 |
| KBio2_007474 |
| KBio3_001493 |
| KBioGR_001172 |
| KBioSS_002341 |
| KS-00000L8X |
| KS-5093 |
| KSC269O8T |
| Kyselina 4-amino-N(sup 10)-methylpteroylglutamova |
| Kyselina 4-amino-N(sup 10)-methylpteroylglutamova [Czech] |
| Kyselina N-(p-((2,4-diamino-6-pteridinylmethyl)methylamino)benzoyl)-L-glutamova |
| Kyselina N-(p-((2,4-diamino-6-pteridinylmethyl)methylamino)benzoyl)-L-glutamova [Czech] |
| L-(+)-AMETHOPTERIN |
| L-(+)-N-(p-(((2,4-Diamino-6-pteridinyl)methyl)methylamino)benzoyl)glutamic acid |
| L-Amethopterin |
| L-Glutamic acid, N-(4-(((2,4-diamino-6-pteridinyl)methyl)methylamino)benzoyl)-, sodium salt |
| L-Glutamic acid,4-diamino-6-pteridinyl)methyl]- methylamino]benzoyl]- |
| L-Glutamic acid,N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-,hydrate(9ci) |
| L-Glutamicacid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]- |
| L-METHOTREXATE |
| Lantarel |
| Ledertrexate |
| Lopac0_000020 |
| LP00020 |
| LS-249 |
| Lumexon |
| Maxtrex |
| MCULE-6523054194 |
| Medsatrexate |
| Metatrexan |
| Metex |
| Methoblastin |
| Methotextrate |
| Methotrate |
| Methotrexat |
| Methotrexat-Ebewe |
| methotrexate |
| Methotrexate 100mg |
| Methotrexate - Abitrexate |
| Methotrexate (JP17/USP/INN) |
| Methotrexate [USAN:INN:BAN:JAN] |
| Methotrexate [USAN:USP:INN:BAN:JAN] |
| Methotrexate 1.0 mg/ml in Dimethyl Sulfoxide |
| Methotrexate for peak identification, European Pharmacopoeia (EP) Reference Standard |
| Methotrexate for system suitability, European Pharmacopoeia (EP) Reference Standard |
| Methotrexate hydrate |
| Methotrexate Lpf |
| Methotrexate Preservative Free |
| METHOTREXATE SODIUM PRESERVATIVE FREE |
| Methotrexate sodium salt |
| Methotrexate, European Pharmacopoeia (EP) Reference Standard |
| Methotrexate, L- |
| Methotrexate, monosodium salt |
| Methotrexate, pharmaceutical secondary standard; traceable to USP and PhEur |
| Methotrexate, PharmaGrade, Manufactured under appropriate controls for use as a raw material in pharma or biopharmaceutical production, meets EP, USP testing specifications |
| Methotrexate, United States Pharmacopeia (USP) Reference Standard |
| METHOTREXATEHYDRATE |
| Methotrexatum |
| Methotrexatum [INN-Latin] |
| Methoxtrexate |
| Methylaminopterin |
| Methylaminopterin hydrate |
| Methylaminopterin; MTX |
| METHYLAMINOPTERINE |
| Methylaminopterinum |
| Metolate |
| Metotressato |
| Metotressato [DCIT] |
| Metotrexato |
| Metotrexato [INN-Spanish] |
| Metrotex |
| Mexate |
| Mexate-Aq |
| Mexate-Aq Preserved |
| MFCD00150847 |
| MFCD28404646 |
| MLS000049968 |
| MLS001401431 |
| MLS002154208 |
| MolPort-003-665-521 |
| MolPort-028-616-821 |
| MPI-2505 |
| MPI-5004 |
| MTX |
| MTX hydrate |
| MTX sodium |
| N-(4-(((2,4-Diamino-6-pteridinyl)methyl)methylamino)benzoyl)-L-glutamicacid |
| N-(4-(((2,4-DIAMINO-6-PTERIDINYL)METHYL)METHYLAMINO)BENZOYL)L-GLUTAMIC ACID |
| N-(4-{[(2,4-Diaminopteridin-1-Ium-6-Yl)methyl](Methyl)amino}benzoyl)-L-Glutamic Acid |
| N-(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}benzoyl)-L-glutamic acid |
| N-(p-(((2,4-Diamino-6-pteridinyl)methyl)methylamino)benzoyl)-L-(+)-glutamic acid |
| N-(p-(((2,4-Diamino-6-pteridyl)methyl)methylamino)benzoyl)glutamic acid |
| N-[(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}phenyl)carbonyl]-L-glutamic acid |
| N-[4-[[(2,4-Diamino-6-pteridinyl)methyl] methylamino]benzoyl]-L-glutamic acid |
| N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid |
| N-{4-[[(2,4-diaminopteridin-6-yl)methyl](methyl)amino]benzoyl}-L-glutamic acid |
| N-Bismethylpteroylglutamic acid |
| NCGC00025060-01 |
| NCGC00025060-02 |
| NCGC00025060-03 |
| NCGC00025060-04 |
| NCGC00025060-05 |
| NCGC00025060-06 |
| NCGC00025060-07 |
| NCGC00025060-08 |
| NCGC00025060-09 |
| NCGC00025060-10 |
| NCGC00025060-11 |
| NCGC00025060-12 |
| NCGC00025060-13 |
| NCGC00025060-15 |
| NCGC00025060-16 |
| NCGC00254216-01 |
| NCGC00260705-01 |
| NCI-C04671 |
| NCIMech_000767 |
| NINDS_000114 |
| Novatrex |
| NSC 740 |
| NSC-740 |
| NSC740 |
| Otrexup |
| Otrexup (TN) |
| Prestwick_322 |
| Prestwick0_000135 |
| Prestwick1_000135 |
| Prestwick2_000135 |
| Q-201366 |
| R 9985 |
| Rasuvo |
| Rheumatrex |
| RTR-020497 |
| s1210 |
| SC-19293 |
| SC-88579 |
| SCHEMBL12421860 |
| SCHEMBL3711 |
| SCHEMBL4135 |
| SMP2_000020 |
| SMR000112001 |
| SMR000449324 |
| Sodium (S)-4-carboxy-4-(4-(((2,4-diaminopteridin-6-yl)methyl)(methyl)amino)benzamido)butanoate |
| Sodium L-(+)-methotrexate |
| Sodium N-(4-(((2,4-diamino-6-pteridinyl)methyl)methylamino)benzoyl)-L-glutamate |
| SPBio_001094 |
| SPBio_002149 |
| Spectrum_001836 |
| Spectrum2_001077 |
| Spectrum3_000497 |
| Spectrum4_000616 |
| Spectrum5_000958 |
| TCMDC-125858 |
| Texate |
| Tocris-1230 |
| Tox21_110944 |
| Tox21_110944_1 |
| Tox21_300269 |
| Tox21_500020 |
| Tremetex |
| Trexall |
| Trexall (TN) |
| Trexeron |
| Trixilem |
| UNII-99ITO15X8S component FBOZXECLQNJBKD-ZDUSSCGKSA-N |
| UNII-YL5FZ2Y5U1 |
| W-105347 |
| W-60383 |
| WLN: T66 BN DN GN JNJ CZ EZ H1N1&R DVMYVQ2VQ |
| WR-19039 |
| X 133 |
| Xatmep |
| Xatmep (TN) |
| YL5FZ2Y5U1 |
| Z1541638527 |
| ZINC1529323 |
US Patents and Regulatory Information for methotrexate sodium
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacia And Upjohn | FOLEX | methotrexate sodium | INJECTABLE;INJECTION | 088954-001 | Oct 24, 1985 | DISCN | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Hospira | METHOTREXATE SODIUM PRESERVATIVE FREE | methotrexate sodium | INJECTABLE;INJECTION | 011719-012 | Apr 13, 2005 | AP | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | |||
| Barr | METHOTREXATE SODIUM | methotrexate sodium | TABLET;ORAL | 081099-001 | Oct 15, 1990 | AB | RX | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | |||
| Mylan Labs Ltd | METHOTREXATE SODIUM PRESERVATIVE FREE | methotrexate sodium | INJECTABLE;INJECTION | 201529-001 | Mar 29, 2012 | AP | RX | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for methotrexate sodium
| Country | Document Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 2614814 | ➤ Try a Free Trial |
| United Kingdom | 201200192 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
For more information try a trial or see the plans and pricing
Serving hundreds of leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Get our Free Drug Patent Bulletin
Join the 27,046 others who get our Drug Patent Expiration Alerts:
- Articles on vital topics
- Fresh industry trends
- Expiring drug patents
- More …
